
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1401450/publications.pdf Version: 2024-02-01



IÃ1/ PC RöNI

#	Article	IF	CITATIONS
1	Estimating the Basic Reproductive Number from Viral Sequence Data. Molecular Biology and Evolution, 2012, 29, 347-357.	8.9	206
2	Molecular Epidemiology Reveals Longâ€Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. Journal of Infectious Diseases, 2010, 201, 1488-1497.	4.0	172
3	Determinants of HIV-1 broadly neutralizing antibody induction. Nature Medicine, 2016, 22, 1260-1267.	30.7	133
4	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases, 2011, 52, 532-539.	5.8	127
5	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. Aids, 2007, 21, 2223-2229.	2.2	117
6	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	12.8	112
7	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. PLoS Pathogens, 2010, 6, e1001123.	4.7	108
8	Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. Clinical Infectious Diseases, 2011, 53, 1271-1279.	5.8	84
9	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2014, 58, 285-294.	5.8	75
10	Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds. PLoS Pathogens, 2015, 11, e1004722.	4.7	68
11	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. Aids, 2010, 24, 1177-1183.	2.2	62
12	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. Journal of Infectious Diseases, 2015, 212, 28-38.	4.0	61
13	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2016, 62, 115-122.	5.8	60
14	Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples. Microbiome, 2017, 5, 94.	11.1	59
15	Metagenomic sequencing complements routine diagnostics in identifying viral pathogens in lung transplant recipients with unknown etiology of respiratory infection. PLoS ONE, 2017, 12, e0177340.	2.5	56
16	Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. PLoS Pathogens, 2018, 14, e1006895.	4.7	53
17	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clinical Infectious Diseases, 2016, 62, 1310-1317.	5.8	52
18	MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. Journal of Virological Methods, 2017, 240, 7-13.	2.1	49

#	Article	IF	CITATIONS
19	Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study. PLoS ONE, 2013, 8, e77691.	2.5	49
20	Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International Collaboration. Journal of Clinical Microbiology, 2014, 52, 517-523.	3.9	47
21	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2016, 214, 399-402.	4.0	47
22	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature, 2018, 561, 406-410.	27.8	47
23	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, e2194-e2202.	5.8	47
24	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology, 2016, 13, 62.	2.0	45
25	High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children. Microorganisms, 2021, 9, 642.	3.6	41
26	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Molecular Biology and Evolution, 2018, 35, 27-37.	8.9	37
27	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. International Journal of Epidemiology, 2014, 43, 887-896.	1.9	36
28	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. Nature Communications, 2021, 12, 6703.	12.8	36
29	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1102-1112.	4.0	35
30	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus–coinfected Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 68, 569-576.	5.8	30
31	Unbiased metagenomic sequencing complements specific routine diagnostic methods and increases chances to detect rare viral strains. Diagnostic Microbiology and Infectious Disease, 2015, 83, 133-138.	1.8	29
32	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. Journal of Experimental Medicine, 2018, 215, 1589-1608.	8.5	29
33	African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. Aids, 2009, 23, 1269-1276.	2.2	28
34	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	4.0	27
35	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clinical Infectious Diseases, 2022, 75, e585-e593.	5.8	26
36	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Journal of Clinical Investigation, 2022, 132, .	8.2	26

#	Article	IF	CITATIONS
37	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. American Journal of Epidemiology, 2014, 179, 1514-1525.	3.4	25
38	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. Journal of Infectious Diseases, 2019, 220, 91-99.	4.0	24
39	Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. Journal of Experimental Medicine, 2019, 216, 2071-2090.	8.5	22
40	The Impact of Surgical Strategy and Rifampin on Treatment Outcome in <i>Cutibacterium</i> Periprosthetic Joint Infections. Clinical Infectious Diseases, 2021, 72, e1064-e1073.	5.8	22
41	Large-scale inference of conjunctive Bayesian networks. Bioinformatics, 2016, 32, i727-i735.	4.1	21
42	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. Aids, 2014, 28, 2231-2239.	2.2	20
43	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. PLoS Computational Biology, 2013, 9, e1003203.	3.2	19
44	Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study. Influenza and Other Respiratory Viruses, 2017, 11, 337-344.	3.4	19
45	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. Clinical Infectious Diseases, 2019, 69, 1489-1497.	5.8	19
46	Does respiratory co-infection facilitate dispersal of SARS-CoV-2? investigation of a super-spreading event in an open-space office. Antimicrobial Resistance and Infection Control, 2020, 9, 191.	4.1	19
47	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PLoS ONE, 2015, 10, e0133028.	2.5	18
48	A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. Scientific Reports, 2016, 6, 32251.	3.3	17
49	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	3.0	17
50	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Virus Evolution, 2018, 4, vey024.	4.9	17
51	Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (Pls) by Boosted PI Containing Regimens. PLoS ONE, 2012, 7, e50307.	2.5	16
52	Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. Retrovirology, 2014, 11, 75.	2.0	16
53	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 2014, 210, 1555-1561.	4.0	16
54	Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup. Retrovirology, 2017, 14, 33.	2.0	16

#	Article	IF	CITATIONS
55	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. ELife, 2017, 6, .	6.0	16
56	Persistent mammalian orthoreovirus, coxsackievirus and adenovirus co-infection in a child with a primary immunodeficiency detected by metagenomic sequencing: a case report. BMC Infectious Diseases, 2018, 18, 33.	2.9	16
57	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. PLoS ONE, 2012, 7, e37983.	2.5	15
58	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. Scientific Reports, 2016, 6, 27580.	3.3	15
59	Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1. Clinical Infectious Diseases, 2017, 64, 295-300.	5.8	14
60	Absenteeism and presenteeism in healthcare workers due to respiratory illness. Infection Control and Hospital Epidemiology, 2021, 42, 268-273.	1.8	14
61	Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program. Clinical Infectious Diseases, 2022, 75, 1723-1731.	5.8	14
62	Metagenomic Virome Sequencing in Living Donor and Recipient Kidney Transplant Pairs Revealed JC Polyomavirus Transmission. Clinical Infectious Diseases, 2019, 69, 987-994.	5.8	13
63	OUP accepted manuscript. Clinical Infectious Diseases, 2019, 68, 561-568.	5.8	13
64	Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa. PLoS Computational Biology, 2019, 15, e1007083.	3.2	11
65	Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs. Microorganisms, 2021, 9, 1700.	3.6	11
66	Generation of a Recombinant Gag Virus-Like-Particle Panel for the Evaluation of p24 Antigen Detection by Diagnostic HIV Tests. PLoS ONE, 2014, 9, e111552.	2.5	11
67	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. Clinical Infectious Diseases, 2020, 70, 297-303.	5.8	10
68	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. Clinical Infectious Diseases, 2021, 72, 2175-2183.	5.8	10
69	Clusters of Sexual Behavior in Human Immunodeficiency Virus–positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. Clinical Infectious Diseases, 2019, 70, 416-424.	5.8	9
70	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. Journal of Antimicrobial Chemotherapy, 2019, 74, 468-472.	3.0	9
71	Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation. Viruses, 2020, 12, 1330.	3.3	9
72	Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. Infection Control and Hospital Epidemiology, 2022, 43, 312-318.	1.8	9

#	Article	IF	CITATIONS
73	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. Trials, 2021, 22, 724.	1.6	9
74	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Open Forum Infectious Diseases, 2018, 5, ofy078.	0.9	8
75	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 517-524.	2.1	7
76	HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection. JCI Insight, 2021, 6, .	5.0	7
77	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLoS Medicine, 2020, 17, e1003397.	8.4	7
78	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv257.	3.0	6
79	The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatients. BMC Infectious Diseases, 2019, 19, 446.	2.9	6
80	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. Journal of Infectious Diseases, 2019, 220, 244-253.	4.0	6
81	Implementation and evaluation of a care bundle for prevention of non-ventilator-associated hospital-acquired pneumonia (nvHAP) – a mixed-methods study protocol for a hybrid type 2 effectiveness-implementation trial. BMC Infectious Diseases, 2020, 20, 603.	2.9	6
82	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. PLoS Computational Biology, 2021, 17, e1009529.	3.2	6
83	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biology, 2020, 18, e3000963.	5.6	6
84	Gammaretrovirus-Specific Antibodies in Free-Ranging and Captive Namibian Cheetahs. Vaccine Journal, 2015, 22, 611-617.	3.1	5
85	Evaluation of the RIDA®GENE RT-PCR assays for detection of sapovirus, astrovirus, adenovirus, and rotavirus in stool samples of adults in Switzerland. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114924.	1.8	5
86	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. Nature Communications, 2020, 11, 5542.	12.8	5
87	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 306-316.	4.0	5
88	Importance of an Early HIV Antibody Differentiation Immunoassay for Detection of Dual Infection with HIV-1 and HIV-2. PLoS ONE, 2016, 11, e0157690.	2.5	4
89	The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study. Swiss Medical Weekly, 2019, 149, w20059.	1.6	4
90	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 1592-1600.	4.0	4

#	Article	IF	CITATIONS
91	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013–2017, in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2020, 71, 637-644.	5.8	3
92	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. Viruses, 2020, 12, 1241.	3.3	3
93	Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. ELife, 2021, 10, .	6.0	3
94	Differences Between Infectious Disease Events in First Liver Transplant Versus Retransplantation in the Swiss Transplant Cohort Study. Liver Transplantation, 2021, 27, 1283-1290.	2.4	3
95	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. Clinical Infectious Diseases, 2022, 74, 1468-1475.	5.8	3
96	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. Open Forum Infectious Diseases, 2022, 9, ofac029.	0.9	3
97	Impact of Latent Tuberculosis on Diabetes. Journal of Infectious Diseases, 2022, 225, 2229-2234.	4.0	3
98	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, , .	4.0	3
99	Use of reverse-transcriptase-based HIV-1 viral load assessment to confirm low viral loads in newly diagnosed patients in Switzerland. BMC Infectious Diseases, 2014, 14, 84.	2.9	2
100	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 72, 1413-1421.	5.8	2
101	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980–2018. Antiviral Therapy, 2020, 25, 43-54.	1.0	2
102	The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. Journal of Infectious Diseases, 2022, 226, 1057-1068.	4.0	2
103	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. Viruses, 2022, 14, 784.	3.3	2
104	Vitamin D deficiency is common in kidney transplant recipients, but is not associated with infections after transplantation. Clinical Transplantation, 2020, 34, e13778.	1.6	1
105	Determinants for voluntary participation in staff screening during an methicillin-resistant Staphylococcus aureus (MRSA) outbreak on a neonatal ward. Infection Control and Hospital Epidemiology, 2021, 42, 881-884.	1.8	1
106	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. Viruses, 2022, 14, 406.	3.3	1
107	Comparison of HIV-1 viral load based on RNA or reverse transcriptase activity in patients with suspected viral load underestimation. Retrovirology, 2012, 9, .	2.0	0
108	Resolution of plasma sample mix-ups through comparison of patient antibody patterns to E. coli. Journal of Immunological Methods, 2015, 427, 130-133.	1.4	0

#	Article	IF	CITATIONS
109	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 508-515.	2.1	0
110	Usefulness of the GenMark ePlex RPP assay for the detection of respiratory viruses compared to the FTD21 multiplex RT-PCR. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115424.	1.8	0
111	Management of Suspected Cases of Feline Immunodeficiency Virus Infection in Eurasian Lynx (Lynx) Tj ETQq1 1	0.784314 2.2	rgBT /Overlo
112	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	2.1	0
113	Impact of an electronic alert on prescription patterns of meropenem, voriconazole and caspofungin. BMC Infectious Diseases, 2021, 21, 1263.	2.9	0
114	Title is missing!. , 2020, 18, e3000963.		0
115	Title is missing!. , 2020, 18, e3000963.		0
116	Title is missing!. , 2020, 18, e3000963.		0
117	Title is missing!. , 2020, 18, e3000963.		0
118	Title is missing!. , 2020, 18, e3000963.		0
119	Title is missing!. , 2020, 18, e3000963.		0
120	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
121	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
122	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
123	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0